cyrilzakka/clinical-trials huggingface dataset:
Effects of VR Training on Balance and Fall Risk of Patients With COPD

The aim of this study is to determine whether Virtual Reality (VR) training has significant effects on balance and fall risk of patients with COPD, with a focus on the patient group (GOLD STANDARD I \&amp; II). Additionally, the study determines whether VR training is a reliable substitute for traditional physical therapy balance.

Chronic Obstructive Pulmonary Disease (COPD) is the forth leading cause of mortality worldwide. COPD often impairs balance due to decreased physical activity, muscle weakness, and compromised respiratory function. Virtual Reality training addresses these issues by offering an immersive and engaging environment that enhances patient motivation and adherence to rehabilitation. The technology allows for personalized and controlled balance exercises, progressively increasing the difficulty to match the patient's skill level and providing real-time feedback. By integrating cognitive and motor tasks, VR promotes a comprehensive approach to balance training, improving sensory integration and postural control.

Research indicates that VR training can enhance both static and dynamic balance, helping patients maintain stability in various conditions. It improves the integration of sensory inputs crucial for balance, while also contributing to muscle strength and endurance. This results in a reduction in fall frequency, as patients become more adept at managing balance and are less likely to fall during daily activities. Additionally, VR training teaches specific fall prevention strategies and boosts patient confidence, which further mitigates the fear of falling-a common issue among COPD patients.

Incorporating VR training into physical therapy programs for COPD patients can be highly beneficial. Its ability to provide engaging and customizable exercises makes it a valuable tool in addressing balance issues and reducing fall risks. However, it is essential to ensure that VR training is conducted under proper supervision to avoid potential accidents, especially in patients with severe COPD or additional health concerns. Overall, VR training represents a significant advancement in rehabilitation, offering a novel and effective approach to managing balance and fall risks in COPD patients. The purpose of study is to determine whether VR training has significant effects on balance and fall risk of patients with COPD (GOLD standard stage I \&amp; II).

Eligibility Criteria:
Inclusion Criteria:

* Both Male and Female
* Diagnosed with mild to moderate COPD (GOLD stages I-II)
* Age between 40-65 years
* BBS score above 35 will be included.
* COPD patients with oxygen saturation of above 88%.
* Patients able to follow instructions / commands.

Exclusion Criteria:

* Recent exacerbation of COPD requiring hospitalization within last 4 weeks.
* Diagnosed with severe cognitive impairments.
* Previous experience with VR-based rehabilitation.
* Use of medication that could affect exercise response.
The Benefits of Nature for Mood and Cognition in Persons With and Without Parkinson's Disease

This online study aims to explore the benefits of nature for mood and cognition in persons with and without Parkinson's disease. For the purpose of this survey, "natural environment" refers to places that primarily consist of natural elements, such as vegetation, water bodies, and landscapes. This includes greenspaces (such as parks, gardens, neighborhood streets lined with trees, forests, or nature reserves) bluespaces (such as next to beaches, lakes, rivers, ponds, or waterfronts), and desert regions, among others.

To participate in this online study, you will need an email address, and a smartphone or laptop/desktop with internet access. If you are eligible to participate, you will be sent a link to an online survey (Qualtrics). We will ask questions about demographic and health information, followed by questions about exercise habits, exposure to natural environments (including greenspaces and bluespaces, among others), and questionnaires assessing mood, motivation, cognition, sleep, stress, quality of life, and related functions. The survey should take roughly 20-25 minutes to complete. This is an observational study only, and not an interventional study.

Compensation: A $15 Amazon gift card will be offered to those who complete the survey all the way through with good effort.

Eligibility Criteria:
Inclusion Criteria:

For persons with Parkinson's disease:

* Participants must be at least 40 years old
* Have a diagnosis of idiopathic PD
* Be proficient English speakers
* Have functional vision
* Have internet access, and access to a smartphone/laptop/desktop

For persons without Parkinson's disease:

* Participants must be healthy middle-aged and older adults, with no diagnosis of neurological/neurodegenerative conditions
* Participants must be at least 40 years old
* Be proficient English speakers
* Have functional vision
* Have internet access, and access to a smartphone/laptop/desktop

Exclusion Criteria (both groups):

* Diagnosis of dementia
* Poor vision (non-functional range)
* Lack of access to internet or to a smartphone/ laptop/desktop computer.
Ovarian Tissue Freezing For Fertility Preservation

The purpose of this study is to offer an alternative method to women who wish to preserve the possibility of fertility, as well as to learn more about the ability of human eggs to survive and function after long term storage in frozen ovaries (ovarian tissue cryopreservation). The study will seek to preserve ovarian tissue and reproductive potential for patients whose medical or surgical treatment may harm ovaries or remove ovarian tissue.

Women who have not yet undergone this procedure, and who present to the Fertility Consultants desiring fertility preservation, will be offered participation in the study.

Subjects will undergo an initial visit which will include a blood draw, ultrasound, and any additional tests or exams that are medically indicated for the subject's diagnosis in preparation for surgery. Subjects will then undergo an oophorectomy surgery (removal of one or both ovaries). Following removal, subject's ovarian tissue will be cryopreserved (frozen) and stored for possible future use. We also plan to collect subjects medical history information to enter into a research database. Subjects will be followed until they decide to use their tissue for fertility purposes.

We will also retrospectively enroll women who have already undergone this procedure by contacting them by mail and offering participation in our ovarian tissue cryopreservation database.

Eligibility Criteria:
Inclusion Criteria:

* Woman between the age of 18-41 years who will undergo surgery, chemotherapy, drug treatment and/or radiation for the treatment or prevention of a medical condition or malignancy expected to result in permanent and complete loss of subsequent ovarian function or have a medical condition or malignancy that requires removal of all or part of one or both ovaries.
* Patients may have newly diagnosed or recurrent disease. Those who were not enrolled at the time of initial diagnosis are eligible if they have not received therapy that is viewed as likely to result in complete and permanent loss of ovarian function.
* For patients undergoing elective removal of an ovary for fertility preservation only, have two ovaries.
* Patients who already have stored cryopreserved ovarian tissue in a frozen state prior to undergoing cancer treatments (surgery, chemotherapy or radiation) will be eligible for enrollment with informed consent.
* Signed an approved informed consent and authorization permitting the release of personal health information. The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent for specimen collection has been obtained, in accordance with institutional policies approved by the U.S. Department of Health and Human Services.

Exclusion Criteria:

* Women with psychological, psychiatric, or other conditions which prevent giving fully informed consent.
* Women whose underlying medical condition significantly increases their risk of complications from anesthesia and surgery.
Apical Support During Hysterectomy for Pelvic Organ Prolapse-NSQIP Analysis.

This is a retrospective descriptive study using the American College of Surgeon's National Surgical Quality Improvement Program® (ACS NSQIP®) data to determine whether gynecologic surgeons are already meeting the recently recommended best practice of supporting the vaginal apex at time of hysterectomy for pelvic organ prolapse (POP).

The prevalence of pelvic organ prolapse (POP) in the United States is estimated to be between 40-50% with an anticipated increase over the next several decades. Approximately 300,000 women undergo surgeries to repair POP in the United States every year. Following pelvic reconstructive surgery, recurrence rates of symptomatic prolapse range between 6-30%.

Our understanding of pelvic anatomy and its support has been significantly improved over recent decades, with many researchers reporting on details and mechanics previously not understood.

In November 2017, the American College of Obstetricians and Gynecologists released a new practice bulletin outlining the current standard of care for the treatment of women with pelvic organ prolapse. In this bulletin, they state that a hysterectomy alone is not adequate treatment for POP, and further that any woman having a hysterectomy for POP should undergo a concurrent apical suspension procedure as a standard of care.

The purpose of this study is to determine the proportion of patients undergoing hysterectomy for the indication of POP having concurrent apical suspension among the population whose cases are reported within the NSQIP database, and who underwent hysterectomy between 2015 and 2017.

Eligibility Criteria:
Inclusion Criteria:

* Underwent hysterectomy for pelvic organ prolapse, between 2015 and 2017

Exclusion Criteria:

* Age \< 18 years old
* Pelvic Organ Prolapse was not recorded in their postoperative diagnoses
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

This study assessed the efficacy and safety of LBH589 as single agent and in combination with ESA in red blood cell transfusion-dependent Low and Int-1 MDS patients being either refractory to ESA or with a low probability of response. The study had a non-randomized core phase followed by a randomized phase.


Eligibility Criteria:
Key Inclusion Criteria:

* Patients with a lower risk MDS (LOW or INT-1 according to IPSS)
* Red blood cell transfusion dependency of at least 4 Units/8 weeks.
* Not responding to Erythropoietin stimulating agents (ESA) or having a low chance to do so
* Age-adjusted normal cardiac, kidney, liver function

Key Exclusion Criteria:

* Concomitant use of ESA
* Concomitant use of any other investigational drug
* Other malignancy that is not in remission for at least 1 year
* Platelet Count \< 75 x 109/L
* Impaired cardiac function or clinically significant cardiac diseases
PuraBond® and Pain Following Resection of Oral or Oropharyngeal Mucosal Lesions

To evaluate the use of Purabond® in transoral resections of primary oral or oropharyngeal lesions for diagnostic and therapeutic procedures. Patients will be enrolled and randomised to either have PuraBond® applied to the surgical field or not intra operatively. The primary outcome measure will assess if this intervention significantly reduces acute pain during the 30 day post-operative period alongside other post-operative complication rates and recovery outcomes.

PuraBond® PROOF is a prospective, single centre, parallel group randomised controlled trial. Transoral approaches in head and neck surgery have become more common given they offer a minimally invasive approach to surgery, thus removing the need for external incisions in the neck. Post operative pain and bleeding are clinically important factor that directly impact patient recovery. PuraBond® is haemostatic agent, classified as a CE marked class III medical device, that is applied to surgical fields and has been shown to be both safe to use and effective in reducing bleeding. This trial will look to investigate the impact of applying PuraBond® in oral cavity or oropharyngeal operations on post-operative pain outcomes. Patients undergoing a pre-determined set of operations in either the mouth or oropharynx will be randomised to either receive PuraBond® to the surgical field during the operation or not. This allocation will be random and both treatments are currently used as part of routine standard clinical practice. Participants will be asked to monitor and record their pain levels pre and post-operatively by marking their pain level on a continuous scale from 'no pain' to 'the worse possible pain' using the Visual Analogue Scale (VAS). Patients will be enrolled from a single tertiary university hospital trust in the United Kingdom (Liverpool University Hospitals Foundation Trust). Case notes of all patients will also be analysed and data on patient demographics and post operative outcomes collated. This will be the first trial to look at PuraBond® use in head and neck surgery with pain being the primary trial outcome.

Eligibility Criteria:
Inclusion Criteria:

* Patient and disease factors are deemed suitable for transoral surgery under general anaesthetic.
* Decision to treat with primary transoral resection or local excision biopsy.
* Written informed consent provided.
* Clinically suspected or histologically confirmed primary dysplasia or malignancy of the oral cavity or oropharynx OR histologically confirmed diagnosis of squamous cell carcinoma in a cervical lymph node of unknown primary.
* Patient considered fit for surgery.

Exclusion Criteria:

* Lesions undergoing incisional or punch biopsy only.
* Surgery with planned primary closure or local/ distant flap reconstruction.
* Inability to provide written informed consent.
* Medical contraindication to a general anaesthetic or to PuraBond® use.
A Phase I Study of LY3502970 in Healthy Participants

The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.


Eligibility Criteria:
Inclusion Criteria:

* Are overtly healthy as determined by medical evaluation
* Participants with body weight of 45 kilograms (kg) or more and body mass index within the range 18.5 to 35.0 kilograms per meter squared (kg/m²), inclusive
* Males who agree to use highly effective or effective methods of contraception and women not of childbearing potential may participate in this study

Exclusion Criteria:

* Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
* Women who are lactating and women of child bearing potential (WOCBP) are excluded from the study
* Participants who regularly use known drugs of abuse or show positive findings on drug screen
Analysis of the Variation of the Retinal Vascularization After a Prolonged Effort

The cardiovascular parameters of prolonged physical exercice have been studied, but very little data is available about the retinal vascularization.

The eye allows in vivo visualization of micro-vascularisation and is considered as an excellent marker of general vascular condition.

The marathon is an intense and prolonged exercise (running 42.195 km) in aerobic environment. Thus the investigators propose to study the vascular parameters of the retina, before and after this physical exercise.

This will allow : 1) to collect information on the physiology of the retinal vascularization to prolonged effort, 2) to detect any retinal damage (haemorrhages, edema, occlusion ...), not known to date.

The results may highlight vascular effects related to retinal hypoxia (venous tortuosity, haemorrhage, venous occlusion, hypoxic edema). Furthermore the results may urge prevention in this sport more and more democratized.

the investigators hypothesized that prolonged physical exercice causes a change in retinal vascularization.


Eligibility Criteria:
Inclusion Criteria:

* Person registered at the 2019 Paris Marathon

Exclusion Criteria:

* Ophthalmological disorders making access to the fundus impossible for both eyes
Implementation of a Combination Intervention for Sustainable Blood Pressure Control

This is a randomized clinical trial intended to identify the optimal strategy of blood pressure management in rural South Africa using Community Health Workers (CHWs) in conjunction with in-home BP monitoring among adults.

We will conduct a trial using CHWs in conjunction with in-home BP monitoring among 774 adults ≥ 18 years old residing in uMkhanyakude District in northern KwaZulu-Natal in an area that is served by a CHW. Eligible participants will be recruited from prior community-based hypertension screening programs, CHW-led hypertension screening activities, and/or from trial clinics where they are accessing care. Consenting participants will be randomized to one of the three study arms of hypertension care (258 participants per arm): 1) clinic-based standard of care model (SOC); 2) community health worker-based blood pressure monitoring model (CHW); 3) and enhanced community health worker-based model, including mobile health blood pressure monitoring model (eCHW+). Independent of clinical care, all participants will be seen at enrollment and at 6 months for BP monitoring and data collection by study nurses for outcome assessments. The primary effectiveness outcome will be assessed in an intention-to-treat analysis and defined as the change in systolic blood pressure (SBP) 6 months after enrollment. The secondary effectiveness outcome will be the proportion of participants with controlled blood pressure, as defined by an SBP \<140 mmHg and a diastolic BP (DBP) \<90 mmHg 6 months after enrollment.

Eligibility Criteria:
Inclusion Criteria:

* Age greater than 18 years old
* Residing in uMkhanyakude District in northern KwaZulu-Natal in an area that is served by a CHW.
* Elevated blood pressure (blood pressure \> 140/90 mmHg) on two measurements.

Exclusion Criteria:

* Pregnant or breast-feeding women.
* Severe, symptomatic hypertension with a measured blood pressure \> 180/110 mmHg.
* Known, advanced chronic kidney disease. GFR \< 60 ml/min/1.73 m2.
* Current use of at least 3 different anti-hypertensive therapies at full dose.
* Planning to move within the next 24 months.
The Effects of the Hopeful Outdoor Parkinson Exercise (HOPE) Program on Improving Balance Performance in Parkinsonian Non-fallers and Single Fallers

To determine whether the 8-week Hopeful Outdoor Parkinson's Exercise (HOPE) Program would be effective in improving balance performance, physical functions, gait parameter, balance confidence, health-related quality-of-life, disease-specific motor performance and fall-related outcomes in Parkinson's disease (PD) non-fallers and single fallers.

Previous studies demonstrated that multi-modal balance training program was effective in improving balance performance in people with PD. However they did not include all the balance domains and outdoor fall-prone activities have been overlooked. We designed a task- and context-specific balance training program based on the framework of the Balance Evaluation Systems Test (BESTest) to target all six balance domains including biomechanical constraints, stability limits and verticality, anticipatory postural adjustments, reactive postural responses, sensori-motor integration and dynamic gait control.

Eligibility Criteria:
Inclusion Criteria:

* diagnosed with PD by a neurologist (Fahn and Elton, 1987);
* aged 30 to 85 years;
* at modified Hoehn and Yahr (H\&Y) stage 1.5 to 3 (Hoehn and Yahr ,1967; Goetz et al., 2004);
* able and willing to give written consent for participation in the study;
* living at home in the community;
* able to walk independently for 30 metres with or without an assistive device.

Exclusion Criteria:

* any neurological conditions other than PD;
* significant musculoskeletal or cardiopulmonary diseases;
* other disorders that may affect balance or locomotion;
* taken any structured behavioral or exercise programs in the past 3 months
* or they are receiving regular physical rehabilitation at present;
* unstable condition on anti-parkinsonian medications;
* surgical interventions for PD;
* communication or cognitive deficits with mini-mental state examination, (MMSE) \<24/30 (Folstein et al., 1975);
* a history of more than two falls in the previous 12 months.
The Self-Compassion Online - Preventing Depression Trial

Purpose: Depression affects 12.6% of Canadians at some point in their life. Depression is associated with staggering personal and economic costs. There are several treatments that have been shown to treat episodes of depression when they occur. Unfortunately, more than half who respond to these treatments go on to re-experience an episode of depression. Even with psychological and pharmacological interventions designed to prevent future episodes, relapse and recurrence of the disorder remain alarmingly high. A patient-focused and self-directed intervention that harnesses the effects of an Eastern-influenced concept, called self-compassion, has shown tremendous promise in treating acute depression. Self-compassion is being moved by one's own suffering, and a desire to alleviate such suffering.

Objectives: In the proposed project, the investigators will examine whether a self-compassion intervention is effective in preventing relapse/recurrence of depression over a 12-month period among people who are at high risk for relapse. The investigators will also examine whether the intervention works to prevent depression by increasing the innate ability to bounce back from stress, a concept known as resilience.

Methodology: 120 participants with a history of depression will be randomly assigned to the self-compassion intervention or a self-assessment reflection condition, and their respective relapse rates will be examined over a period of 12 months.

Importance to Research: This will be the first study to examine the effects of self-compassion as a preventive intervention for depression.

Impact on health: If successful, this new intervention can be used by thousands of people in Saskatchewan and Canada who are at risk for depression relapse.


Eligibility Criteria:
Inclusion Criteria:

* To be eligible to participate in the study, participants must be: a) 18 years old or older; b) have experienced at least one episode of depression; and c) exhibit elevated residual symptoms of depression-as indicated by a score of 5 or more on the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, \& Williams, 2001). As the majority of people experience both depression and anxiety symptoms concurrently, participants experiencing elevated anxiety symptoms will not be excluded from the study.

Exclusion Criteria:

* Participants will be excluded from the study if they indicate: a) a current diagnosis MDD, substance use disorder, psychosis, or mania in accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5; American Psychiatric Association, 2013); b) the presence of major health conditions (e.g., cardiovascular diseases, cancer, hypothyroidism, etc.); and c) currently undergoing psychological or pharmacological treatment at the time of recruitment